Glenmark Progresses Novel Pain Asset With Partnering In Mind
Glenmark is moving ahead with studies for its inhibitor of mPGES-1 amid cautious optimism. Pain management is, however, not a core thrust for the Indian firm and it hopes to out-license the potential first-in-class molecule at some stage.
You may also be interested in...
Glenmark Eyes Blockbuster Status For First In-House Biologic
Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.
Deals Shaping The Medical Industry, November 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
INTERVIEW: GNT To Rise Again With New Clinical Development Strategy
GNT Pharma, which failed to progress its clinical pipeline amid global financial woes several years ago, aims to get back on its feet with the help of a new development strategy and improved regulations. The South Korean company's CEO sat down with PharmAsia News to talk about the first-in-class stroke therapy Neu2000 and what the company aims to achieve.